People & Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

Dr. Sarah Donaldson, Dr. Robert Kyle, Dr. Scott Lippman

Dr. Sarah Donaldson

ASCO presented the 2007 Pediatric Oncology Award to Sarah S. Donaldson, MD, professor of radiation oncology at Stanford Comprehensive Cancer Center in California. Dr. Donaldson was recognized for her work in increasing the understanding of and the cure rates for various childhood cancers. She also serves as associate chair of radiation oncology at Stanford University School of Medicine.

Dr. Robert Kyle

Robert A. Kyle, MD, professor of medicine and laboratory medicine at the Mayo Medical School, Rochester, Minnesota, was awarded the David A. Karnofsky Memorial Award at ASCO 2007 for his extensive research in hematology. He is director of the Scientific Advisory Board for the International Myeloma Foundation and chairman of ECOG's Myeloma Committee.

Dr. Scott Lippman

The American Cancer Society Award was given to Scott M. Lippman, MD, at ASCO 2007 in recognition of his work in cancer prevention. Dr. Lippman chairs the Department of Clinical Cancer Prevention at M.D. Anderson Cancer Center and is professor of both clinical cancer prevention and thoracic/head and neck medical oncology. His research interests are focused on translational chemoprevention studies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.